III Brazilian Registry of Heart Failure

Официальное название

BREATHE III - THIRD PHASE OF THE BRAZILIAN HEART FAILURE REGISTRY

Обзор

BREATHE III is a prospective, multicenter, observational registry designed to provide contemporary insights into the epidemiological, clinical, and prognostic characteristics of patients hospitalized with acute heart failure (AHF) in Brazil, including those with decompensated heart failure or new-onset ventricular dysfunction during acute myocardial infarction. Recent evidence, such as the STRONG-HF trial, has demonstrated the prognostic benefit of rapid initiation and up-titration of guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF). However, prior phases of the BREATHE registry did not evaluate the timing of therapeutic optimization or barriers to implementing these strategies. Additionally, the therapeutic landscape of heart failure has evolved substantially in recent years, with the introduction of novel pharmacological agents, expanded indications for existing therapies, and new treatment options for heart failure with preserved ejection fraction (HFpEF). BREATHE III aims to address these knowledge gaps by systematically assessing, over a 12-month follow-up, patient characteristics, treatment patterns, adherence to guideline-recommended therapies, time to treatment optimization, and clinical outcomes. The study will also identify barriers to the implementation and titration of evidence-based therapies, evaluate regional variations in care, and describe contemporary management practices across public and private healthcare settings in Brazil. The results of this registry are expected to inform strategies to improve quality of care, optimize resource allocation, and guide future interventions aimed at reducing morbidity and mortality associated with heart failure in Brazil.

Первичные конечные точки

• All-cause mortality [Срок оценки: 12 months]

Вторичные конечные точки (7)

• Length of hospital stay [Срок оценки: 12 months]
• Composite outcome of death and rehospitalization [Срок оценки: 12 months]
• General rehospitalization, rehospitalization due to heart failure and emergency visits [Срок оценки: 12 months]
• Cardiovascular death [Срок оценки: 12 months]
• Composite outcome of cardiovascular death and rehospitalization due to heart failure [Срок оценки: 12 months]
• Proportion of patients receiving interventions with proven benefit demonstrated by different indicators of quality of care (at target dose) [Срок оценки: 12 months]
• Quality of life according to the Minnesota Living with Heart Failure Questionnaire (MLHFQ) [Срок оценки: 12 months]

Критерии участия

Критерии включения

Adult patients (≥ 18 years) admitted to public and private hospitals with one of the two clinical conditions below:

• Admission for AMI (Acute Myocardial Infarction) presenting with reduced ejection fraction during hospitalization (LVEF ≤ 40%) and which had not been previously identified (limit of 25% of the study sample included by this criterion)
• Primary diagnosis of decompensated HF (regardless of ejection fraction), with the HF diagnosis established according to the universal definition of heart failure. In cases of HF with HFpEF, in addition to the data from the universal heart failure criteria, H2FPEF and HFA PEFF data will be collected.

Критерии исключения

• Refusal to participate in the study during the informed consent process;
• Surgical myocardial revascularization in the last month;
• Heart failure secondary to sepsis (sepsis as the origin of heart failure);
• Cardiogenic shock.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Публикации

• DE Albuquerque DC, DE Barros E Silva PGM, Lopes RD, Hoffmann-Filho CR, Nogueira PR, Reis H, Nishijuka FA, Martins SM, DE Figueiredo Neto JA, Pavanello R, DE Souza Neto JD, Danzmann LC, Gemelli JR, Rohde LEP, Hernandes ME, Rivera MAM, Simoes MV, Dos Santos ES, Canesin MF, Zilli AC, Santos RHN, Jesuino IA, Mourilhe-Rocha R, Moura LZ, Marcondes-Braga FG, Mesquita ET; BREATHE INVESTIGATORS. In-Hospita PMID 37648061

Идентификаторы

NCT: NCT07534163 · BREATHE III

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗